You are here

MSC-Induced Kidney Transplant Tolerance

A case report published in STEM CELLS Translational Medicine provides the first evidence that autologous bone marrow‐derived mesenchymal stromal cells (MSC) infusion associates with safe, complete discontinuation of maintenance antirejection drugs late after living‐donor kidney transplantation, eventually allowing a state of operational tolerance. Researchers led by Giuseppe Remuzzi (Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy) believe that this case may provide a basis for future studies assessing whether a panel of non-invasive immunomonitoring tools, in addition to clinical criteria, could identify a pro‐tolerogenic signature after MSC therapy that could eventually help to identify patients who are amenable to safe immunosuppressive drug discontinuation. Casiraghi et al. note the requirement of further investigations building on this approach in living‐donor as well as in deceased-donor kidney transplantation.